Region:   International United States Sweden

May 3, 2022  ·  Regulatory information

Bioservo Technologies AB Interim Report January – March 2022

First quarter in figures

  • Net sales of SEK 2.9 M (1.5)
  • EBITDA of SEK -11.0 M (-7.8)
  • EBIT of SEK -12.1 M (-9.0)
  • Earnings for the period amounted to SEK -12.1 M (-9.0)
  • Earnings per share before and after dilution amounted to SEK -0.64 (-0.57)
  • Cash flow from operating activities for the period amounted to SEK -12.3 M (-7.7)

Significant events during the period

  • Nishio Rent All Co Ltd orders 10 Ironhand® 2.0 systems with an order value of 500 kSEK. The order is a result of an increased interest in Ironhand from industrial customers in Japan.
  • Appointment of Ironhand Sales Manager in the US to support our distributor partners and ensure successful commercialization in the US.

Events after the end of the period

  • Appointment of Nordic Sales Manager for Life Science to launch a new version of Carbonhand in connection with expected positive results from the previous IH study.

For further information please contact:

Petter Bäckgren, CEO
+46 8 21 17 10


Madeleine Börjesson, CFO
+46 8 21 17 10

Note: This information is such as is required by Bioservo Technologies AB under the EU Market Abuse Regulation. The information was submitted, through the care of the above person, for publication on 3 May 2022 at 08:30 (CET).

About Bioservo Technologies

Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, is the company’s Certified Adviser on Nasdaq First North

For more information, please visit